Navigation Links
Study Results of GAMMAGARD S/D and GAMMAGARD LIQUID in Patients with Mild-to-Moderate Alzheimer's Disease Announced
Date:4/17/2008

tal X-linked agammaglobulinemia, common variable immunodeficiency, Wiskott-Aldrich syndrome, and severe combined immunodeficiencies.

GAMMAGARD S/D must not be used in patients with selective IgA deficiency (IgA < 0.05 g/L) where the IgA deficiency is the only abnormality of concern.

Important Safety Information

Patients may experience severe hypersensitivity reactions or anaphylaxis in the setting of detectable IgA levels following infusion of GAMMAGARD S/D.

Immune Globulin Intravenous (Human) products have been reported to be associated with renal dysfunction, acute renal failure, osmotic nephrosis, and death. Patients predisposed to acute renal failure include patients with any degree of pre-existing renal insufficiency, diabetes mellitus, age greater than 65, volume depletion, sepsis, paraproteinemia, or patients receiving known nephrotoxic drugs. Especially in such patients, IGIV products should be administered at the minimum concentration available and the minimum rate of infusion practicable. While these reports of renal dysfunction and acute renal failure have been associated with the use of many of the licensed IGIV products, those containing sucrose as a stabilizer accounted for a disproportionate share of the total number.

GAMMAGARD S/D does not contain sucrose.

GAMMAGARD S/D is made from human plasma. It may carry a risk of transmitting infectious agents, e.g. viruses, and theoretically, the Creutzfeldt-Jakob disease (CJD) agent.

Aseptic meningitis syndrome (AMS) has been reported to occur infrequently in association with IGIV treatment. Discontinuation of IGIV treatment has resulted in remission of AMS within several days without sequelae.

Certain components used in the packaging of GAMMAGARD S/D contain natural rubber latex.

IGIV products can contain blood group antibodies that may cause a positive direct antiglobulin reaction and, rarely, hemolysis.

Thrombotic events have been report
'/>"/>

SOURCE Baxter International Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
4. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
5. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
6. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
7. Study Suggests High-Dose Fish Oil May Significantly Improve Behavior in Children with ADHD
8. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
9. Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
10. MacroGenics Begins Global Phase 2/3 Protege Study in Recent-onset Type 1 Diabetes Mellitus
11. Sarasotas Roskamp Institute Releases Study Defining a Mechanism for Development of Obesity and the Metabolic Syndrome, Forerunners of Type 2 Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... -- Ambit Biosciences (Nasdaq: AMBI ), a biopharmaceutical company ... in oncology, autoimmune and inflammatory disease, today announced the Company,s ... held at The New York Palace Hotel in ... Alan Fuhrman , Ambit,s CFO, will provide an ... at 1:10 p.m. ET on Wednesday, September 3, 2014.  The ...
(Date:8/27/2014)... Aug. 27, 2014  After the February 2014 launch ... billing solution for medical practices and management companies, ... the new software. "The feedback has been ... . "The sheer number of demos and new sign-ups ... was for these types of software features." ...
(Date:8/27/2014)... , Aug. 27, 2014  Zimmer Holdings, Inc. (NYSE ... announced that it will be participating in the Morgan ... in New York, New York , ... President and CEO of Zimmer, will be presenting at ... and CEO of Biomet, will join Mr. Dvorak for ...
Breaking Medicine Technology:Ambit Announces Participation At Baird 2014 Health Care Conference 2Medical Software Company, Prime Clinical Systems, Sees Excellent Response to their Workers' Compensation Solutions 2Medical Software Company, Prime Clinical Systems, Sees Excellent Response to their Workers' Compensation Solutions 3
... PHILADELPHIA, Oct. 5 GlaxoSmithKline [NYSE: GSK] today ... Administration,s (FDA) Oncologic Drugs Advisory Committee (ODAC) voted ... (pazopanib). Specifically, the panel voted that the benefit-to-risk ... cell carcinoma (RCC). Pazopanib is an investigational, oral ...
... PALO ALTO, Calif., Oct. 5 PEAK Surgical, Inc. ... an agreement that grants the Surgical Technologies business at ... the PEAK PlasmaBlade® TnA (Tonsil and Adenoid) tissue dissection ... , "PEAK,s agreement with Medtronic is a major ...
Cached Medicine Technology:GlaxoSmithKline Receives Unanimous FDA Panel Approval Recommendation for VOTRIENT(TM) 2GlaxoSmithKline Receives Unanimous FDA Panel Approval Recommendation for VOTRIENT(TM) 3PEAK Surgical and Medtronic Announce Global Distribution Agreement for the Ear, Nose, and Throat Market 2PEAK Surgical and Medtronic Announce Global Distribution Agreement for the Ear, Nose, and Throat Market 3
(Date:8/27/2014)... 2014 Power morcellator lawsuits ( http://www.gynecaremorcellatorlawsuit.com/ ... behalf of women who allegedly experienced the spread of ... reports. According to court documents, one of the most ... U.S. District Court, Northern District of New York, on ... of a power morcellator manufactured Karl Storz Endoscopy - ...
(Date:8/27/2014)... What’s next for 14 year old Sriram Hathwar, ... Spelling Bee? Sririam will visit Philadelphia on Friday, August ... Eye Hospital.     , The teen from Painted Post, New ... , Wills Eye Ophthalmologist-in-Chief, Dr. Julia Haller will show ... diagnostic testing. He will also tour historic Philadelphia ...
(Date:8/27/2014)... The newest Abington Health Center ... 8, 2014. This new 15,000 square foot, $5 million ... care practices and walk-in laboratory services. , ... endeavor for Abington Health as the healthcare landscape changes,” ... “Establishing a location in Lower Gwynedd allows us to ...
(Date:8/27/2014)... -- Overconfident people are better at convincing others that ... are more likely to get promotions and reach high-level ... that these "self-deceived" people are also more likely to ... And finally, people who underestimate themselves are regarded ... British researchers. Their findings were published Aug. 27 in ...
(Date:8/27/2014)... Recent growth in health care spending for commercially ... for medical services, rather than increased use, according to ... Institute for Health Policy & Clinical Practice, published in ... Managed Care . , There is increasing concern that ... increased prices faced by payers and, ultimately, consumers," said ...
Breaking Medicine News(10 mins):Health News:Power Morcellator Lawsuit Alleges Storz Morcellator Caused Spread of Aggressive Uterine Cancer, Bernstein Liebhard LLP Reports 2Health News:Power Morcellator Lawsuit Alleges Storz Morcellator Caused Spread of Aggressive Uterine Cancer, Bernstein Liebhard LLP Reports 3Health News:Power Morcellator Lawsuit Alleges Storz Morcellator Caused Spread of Aggressive Uterine Cancer, Bernstein Liebhard LLP Reports 4Health News:Scripps National Spelling Bee Co-Champion and Aspiring Ophthalmologist Coming to Wills Eye Hospital in Philadelphia 2Health News:Abington Health Opens New Health Center in Lower Gwynedd 2Health News:Overconfident Folks May Blind Others to Their Real Abilities 2Health News:Tracking spending among the commercially insured 2
... Lancet Neurology says that the fact that first-borns have a ... myth. Birth order of the children does not increase their ... // have any affect on the incidence of multiple sclerosis., ... a role in MS. Previous research has reported a higher ...
... A new study indicates that a combination of surgery ... patients suffering from spinal cord compression. //, ,Metastatic ... common complication of cancer, occurring in 5 to 14 ... of corticosteroids and radiotherapy - after which only 50 ...
... also been under intense scrutiny to look at their ... and 25 other related conditions) and HIV. // , ... lover of all, Casanova in the 17th century was ... against infection. The question now is that how much ...
... the genetic pathway involved in the development of hearing. Research ... ear –– the cells largely responsible for hearing // ... ,Situated in the hearing portion of the inner ... the ear in the form of sound waves into chemical ...
... claimed at least 20 lives in the past two weeks ... already present in the neighboring Indian state of UP // ... 10 deaths each in the townships of Tikapur and Dhangadi ... 80 patients were undergoing treatment in various hospitals and health ...
... slowly spreading in UP and causing more deaths especially in ... caused by the rapidly spreading killer virus // in ... disease was so far confined largely to Gorakhpur and neighboring ... only nearby Bahraich, Barabanki and Lakhimpur-Kheri districts but also to ...
Cached Medicine News:Health News:"An Armour against pleasure, and a cobweb against infection" – Has the condom withstood the test of time 2Health News:"An Armour against pleasure, and a cobweb against infection" – Has the condom withstood the test of time 3Health News:"An Armour against pleasure, and a cobweb against infection" – Has the condom withstood the test of time 4Health News:Encephalitis Claims 131 lives in Uttar Pradesh 2
Liquichek Pediatric Control is a product designed to monitor important analytes for neonatal testing. This control monitors four bilirubin parameters at two clinically significant levels....
... Chemistry Control (Human) provides a comprehensive ... enzymes and CO2. It requires no ... most major instruments and methodologies. Available ... fill sizes (10 mL fill size ...
Liquid Assayed and Unassayed Multiqual Controls are comprehensive, liquid, human serum based chemistry controls, available in three levels....
Lyphochek® Drug Free Serum can serve as a drug-free baseline for HPLC analysis or as a negative control....
Medicine Products: